WALTHAM, Mass., March 30, 2022 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced Morphic COO and CFO Marc Schegerin, M.D. will participate in panel discussion titled “Novel Approaches Tackling Autoimmune Conditions” at the BMO Biopharma Spotlight Series on Inflammation & Immunology on Wednesday April 6th 2022.
About Morphic Therapeutic
Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen, and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.
Contacts
Morphic Therapeutic
Chris Erdman
chris.erdman@morphictx.com
617.686.1718
DELRAY BEACH, Fla., Aug. 11, 2025 /PRNewswire/ -- The smart textiles market is projected to grow…
DELRAY BEACH, Fla., Aug. 11, 2025 /PRNewswire/ -- The global Flow Cytometry Market, valued at US$4.87…
Emmanuel Ligner, Seasoned Leader with Proven Track Record of Value Creation in Life Sciences, to…
MADISON, Wis., Aug. 11, 2025 /PRNewswire/ -- Nordic®, a global health and technology consulting company,…
AHMEDABAD, India, Aug. 11, 2025 /PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals,…
PLANTATION, Fla., Aug. 11, 2025 /PRNewswire/ -- Everise, a global leader in transforming customer experiences,…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="1px" width="1px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
